Voloridge Investment Management LLC Purchases Shares of 79,071 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Voloridge Investment Management LLC purchased a new stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 79,071 shares of the company's stock, valued at approximately $1,045,000. Voloridge Investment Management LLC owned about 0.09% of Syndax Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also modified their holdings of SNDX. Soleus Capital Management L.P. increased its holdings in shares of Syndax Pharmaceuticals by 128.4% during the fourth quarter. Soleus Capital Management L.P. now owns 2,492,000 shares of the company's stock valued at $32,944,000 after acquiring an additional 1,401,016 shares in the last quarter. Twinbeech Capital LP increased its holdings in Syndax Pharmaceuticals by 79.2% in the 4th quarter. Twinbeech Capital LP now owns 355,900 shares of the company's stock worth $4,705,000 after buying an additional 157,321 shares during the period. Tang Capital Management LLC acquired a new position in Syndax Pharmaceuticals in the 4th quarter worth approximately $1,322,000. Sphera Funds Management LTD. increased its holdings in Syndax Pharmaceuticals by 33.5% in the 4th quarter. Sphera Funds Management LTD. now owns 1,381,241 shares of the company's stock worth $18,260,000 after buying an additional 346,395 shares during the period. Finally, Rafferty Asset Management LLC increased its holdings in Syndax Pharmaceuticals by 3.9% in the 4th quarter. Rafferty Asset Management LLC now owns 178,165 shares of the company's stock worth $2,355,000 after buying an additional 6,643 shares during the period.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on SNDX shares. JPMorgan Chase & Co. lifted their target price on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a research report on Thursday, March 20th. Scotiabank boosted their target price on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a "sector perform" rating in a research note on Tuesday, May 6th. Wall Street Zen raised shares of Syndax Pharmaceuticals to a "sell" rating in a research note on Tuesday, May 6th. Citigroup cut their target price on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Finally, HC Wainwright restated a "buy" rating and issued a $51.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $35.91.

Syndax Pharmaceuticals Trading Up 1.9%

SNDX stock traded up $0.21 during midday trading on Tuesday, hitting $11.19. 1,335,141 shares of the company's stock were exchanged, compared to its average volume of 1,789,693. Syndax Pharmaceuticals, Inc. has a 12-month low of $8.58 and a 12-month high of $25.07. The firm has a 50 day moving average price of $11.40 and a 200-day moving average price of $13.35. The stock has a market capitalization of $962.87 million, a price-to-earnings ratio of -3.08 and a beta of 0.82.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.04) by $0.06. The business had revenue of $20.04 million for the quarter, compared to analysts' expectations of $15.88 million. Syndax Pharmaceuticals's revenue for the quarter was up 1900.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.85) earnings per share. On average, sell-side analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).